Hematology

Supplemental biologics license application is based on positive results from the phase 3 XTEND-Kids study, demonstrating highly effective bleed protection with once weekly dosing of Altuviiio for children with severe hemophilia A.

Improved classification of different lymphoma types can improve the potential of targeted therapies and help predict patient responses.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

A low dose of the combination treatment inhibited AML cell cycle and increased apoptosis.

Crovalimab achieved disease control and non-inferiority compared to eculizumab, which is the current standard-of-care for individuals with paroxysmal nocturnal hemoglobinuria.

Mezigdomide boosted T cell activity and worked in patients with multiple myeloma who were resistant to prior therapeutic agents.

Sodium chloride injection contains sodium chloride in water and is administered intravenously, which is intended for a single-dose injection to replenish fluids and electrolytes.

Luspatercept-aamt (Reblozyl) approved to treat adults with very low- to intermediate-risk myelodysplastic syndrome who may require regular red blood cell transfusions.

Although the patient demographics are similar for the 3 categories of hemolytic reactions with intravenous immunoglobulin, the reaction with delayed hemolytic transfusion reactions was highest compared to the other 2 hemolytic reactions.

Consumerization of health care solutions is connected to a growing desire of patients to have accessible health care/health data and an individualized care experience.

The drug showed statistically significant and clinically meaningful efficacy results across key subgroups.

Prior to this study, anti-platelet factor 4 disorder was thought to be caused by exposure to heparin or autoimmune conditions.

Pharmacists can improve both quality of life and financial toxicity for patients.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The growing awareness in health care of the challenges associated with proper dosing of anticoagulants such as heparin has inspired the emerging field of anticoagulation stewardship.

Pharmacists also have the resources to help advocate for better care for patients.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Pharmacists will play a significant role in TKI adherence rates among patients.

Although additional studies are needed, findings indicate that mtDNAfb may be a useful biomarker for future risk of non-Hodgkin lymphoma.

Improved prescription information could help consumers make better health care decisions and result in cost savings.

The findings suggest that cigarette smoking is an independent predictor for the expansion of hematoma, although smoking status does not cause a difference in mortality.

With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.

Reduced quality of life was observed in patients with hemophilia who were unemployed, had blood-borne illnesses, or had a high annual bleeding rate.